The 14-3-3r, upregulated by p53 in response to DNA damage, can have a positive-feedback impact driving p53 activities and is a human cancer epithelial marker downregulated in various tumors. However, the precise roles of 14-3-3r during tumorigenesis are not well characterized. Here, we show that 14-3-3r is a critical regulator of murine double minute oncogene (MDM2). 14-3-3r interacts with MDM2 at the RING domain. The C-terminal region of 14-3-3r binds to MDM2 very efficiently. Importantly, 14-3-3r overexpression leads to destabilization of MDM2 through enhancing MDM2 selfubiquitination and accelerating turnover rate. Conversely, loss of 14-3-3r results in a significant increase in MDM2 protein. Moreover, live-cell images indicated that 14-3-3r can affect the location of MDM2 from the nucleus to the cytoplasm, and that MDM2-mediated cytoplasmic localization of p53 can be reversed by the presence of 14-3-3r. Significantly, we further showed that 14-3-3r causes MDM2 downregulation, thereby stabilizing p53 and inhibiting tumor growth in animal tumors. Also, 14-3-3r blocks MDM2-mediated retinoblastoma degradation and p53 NEDDylation. Our results provide evidence that 14-3-3r is a pivotal MDM2 regulator involved in blocking a variety of activities of MDM2.
Introduction
Murine double minute oncogene (MDM2), an E3 ubiquitin ligase for tumor suppressor p53, can decrease the stability and half-life of p53 through the ubiquitinproteasome pathway (Iwakuma and Lozano, 2003) , thereby functioning as a protooncogene. Importantly, MDM2 is amplified and overexpressed in several types of human malignancy, including sarcomas, breast carcinomas and brain tumors (Oliner et al., 1992; Momand et al., 1998) . MDM2 is regulated by negative regulators including ADP-ribosylation factor, promyelocytic leukemia and ribosomal proteins L5, L11, L23, but positively regulated by Gankyrin, YY1 and kinase associated phosphatase 1 (reviewed in Lee and Lozano, 2006) . Understanding the molecular pathways controlling the MDM2 activity may shed light on strategic design for MDM2-activated cancer. Indeed, a strategy to activate p53 in tumor by inhibiting MDM2 activity has been the focus in cancer drug discovery. We previously showed that 14-3-3s inhibits MDM2-mediated p53 ubiquitination (Yang et al., 2003) . Thus, 14-3-3s is a potential negative regulator of MDM2. However, the mechanism by which 14-3-3s antagonizes MDM2 activities remains to be characterized. The 14-3-3 family is highly conserved over a wide range of mammalian species, including seven isotypes b, e, Z, g, t (also called y), z and s. Among the family members, 14-3-3s is unique. 14-3-3s is the only 14-3-3 isotype induced by tumor suppressor protein p53 in response to DNA damage (Hermeking et al., 1997) . During the DNA damage process, 14-3-3s blocks CDK activity (Chan et al., 1999; Laronga et al., 2000) and also positively regulates p53 stability and potentiates p53 transcriptional activity (Yang et al., 2003) . Also, the 14-3-3s is downregulated in breast cancers (Ferguson et al., 2000; Yang et al., 2006) . These observations suggest that 14-3-3s protein is involved in p53 network control, playing a role in tumorigenesis. However, the detailed regulation is not well characterized. Here, we assessed the roles of 14-3-3s in regulating MDM2 stability and function. We found that 14-3-3s interacts with and decreases the stability of MDM2. We discovered that 14-3-3s enhances MDM2-mediated selfubiquitination, thus accelerating MDM2 degradation. Also, live-cell images indicated that 14-3-3s affected the location of MDM2 from the nucleus to the cytoplasm; therefore, MDM2-mediated cytoplasmic localization of p53 is reversed by the presence of 14-3-3s. We showed that 14-3-3s expression antagonized MDM2-mediated retinoblastoma (RB) degradation and reduced the level of p53 NEDDylation facilitated by MDM2. Thus, our studies indicate that 14-3-3s is an important negative regulator of MDM2, exerting an inhibitory effect on MDM2-mediated p53 nuclear export, p53 NEDDylation and RB degradation.
Results

14-3-3s interacts with MDM2
We previously showed that 14-3-3s is involved in regulating p53 network by antagonizing the negative impact of MDM2 toward p53 (Yang et al., 2003) . However, it remains unclear whether 14-3-3s interacts with MDM2 physically. Here, we showed that exogenous 14-3-3s interacts with MDM2 in vivo as characterized by coimmunoprecipitation (co-ip) experiments (Figure 1a) . We further confirmed the binding between endogenous proteins in H1299 lung carcinoma cells (p53 null) (Figure 1b) . We also demonstrated the specificity of the interaction between 14-3-3s and MDM2 in a defined system with the glutathione-S-transferase (GST) pull-down (PD) assay. GST-tagged MDM2 was able to bind to in vitro-translated,
35
S-labeled 14-3-3s ( Figure 1c ). The binding specificity and affinity of 14-3-3s protein is modulated by the phosphorylation of MDM2, as we have shown that MDM2 associates with 14-3-3s with less efficiency when phosphatase inhibitor, such as NaF or sodium orthovanadate, is absent ( Figure 1d ).
We then mapped the possible region of 14-3-3s that is involved in binding to MDM2. We showed that the C-terminal region of 14-3-3s (153-248 aa) bound to MDM2 very efficiently when compared with other domains (Figure 2a) as determined by the ratio of bound MDM2 to 14-3-3s constructs (quantitated by densitometer, data not shown).
We also determined the binding site of 14-3-3s on MDM2 by performing a co-ip assay. MDM2 (1-440 aa) is a protein with a deletion in the RING domain (440-491 aa), while MDM2 (50-491 aa) contains RING domain but no p53-binding domain. Two other mutants of MDM2 (MDM2 D220-437 and MDM2 C464A) were also used in the experiments. Nuclear export mutant MDM2 (C464A), which cannot mediate p53 nuclear export (Geyer et al., 2000) , was also included. We found that 14-3-3s was able to bind to other mutants but not to MDM2 (1-440 aa), suggesting that C-terminal MDM2 that contains RING domain is involved in 14-3-3s binding (Figure 2b ). We previously showed that 14-3-3s is able to bind to p53 very strongly, but the binding site of 14-3-3s on p53 remains to be determined. We performed a co-ip assay and found that 14-3-3s was able to bind to other wild type p53 but not two mutants of p53 (DC16 and DC30), two proteins containing the deletion in the very C-terminal 16 or 30 aa of p53. These data indicated that C terminus of p53 is involved in 14-3-3s binding (Figure 2c ). It is notable that the 14-3-3 family member forms dimmer through N-terminal domain and usually uses the C-terminal domain to interact with targeted proteins (Fu et al., 2000) . Together, 14-3-3r as a negative regulator of MDM2 H-Y Yang et al these results suggest that 14-3-3s may form dimmer and appears to use the C-terminal domain to interact with the C-terminal domains of MDM2 or p53 (see model in Figure 7a ).
14-3-3s is involved in regulating MDM2 stability
We previously showed that 14-3-3s can block MDM2-mediated p53 degradation (Yang et al., 2003) . It has been unclear how 14-3-3s exerts its negative impact. We have found that 14-3-3s associates with MDM2 ( Figure 1 ). To address the significance of the interaction, we examined the role of 14-3-3s's activity in regulating the protein level of MDM2 by transfection. Significantly, the expression level of MDM2 was decreased when high level of 14-3-3s was present ( Figure 3a ). MDM2 is an E3 ubiquitin ligase for itself and is involved in regulating the stability and half-life of itself through ubiquitin-proteasome pathway (Fang et al., 2000) . To address the 14-3-3s-mediated MDM2 downregulation issue further, we determined whether 14-3-3s could accelerate MDM2-mediated self-ubiquitination, thereby reducing the stability of MDM2. Cells were co-transfected with MDM2, pCMV-His-ubiquitin and increasing amounts of 14-3-3s into H1299 cells. Cells were harvested and analysed by His-Bind resin binding for the presence of His-ubiquitin containing MDM2. MDM2 can act as ubiquitin ligase and will add His-ubiquitin onto itself. We found that 14-3-3s accelerated MDM2-mediated self-ubiquitination activity ( Figure 3b ).
To determine further whether 14-3-3s functions as a negative regulator of MDM2 under physiological condition, we investigated 14-3-3s's impact on MDM2 in cells deficient in 14-3-3s expression (HCT116 14-3-3sÀ/À cells) (Chan et al., 1999) . We found that less levels of MDM2 are present in HCT116 14-3-3s þ / þ cells compared to HCT116 14-3-3sÀ/À cells ( Figure 3c ). Consistently, we determined the protein turnover of MDM2 by cycloheximide treatment in HCT116 14-3-3sÀ/À and 14-3-3s þ / þ cells and found that the HCT116 14-3-3sÀ/À cells exhibited a reduced MDM2 turnover as compared with HCT116 14-3-3s þ / þ cells ( Figure 3d ). The turnover rate of MDM2 was slower in HCT116 14-3-3sÀ/À cells than that in HCT116 14-3-3s þ / þ cells ( Figure 3e ). Taken together, 14-3-3s can downregulate MDM2 by accelerating the ubiquitinmediated proteasome degradation of MDM2. In keeping with the idea, disabling 14-3-3s results in MDM2 stabilization.
14-3-3s affects the subcellular localization of MDM2 It is known that 14-3-3 can exert its biological function by regulating subcellular localization of its target proteins. We then determined whether 14-3-3s has an 14-3-3r as a negative regulator of MDM2 H-Y Yang et al impact on MDM2 nuclear localization. The H1299 cells were transfected with GFP-MDM2 and then infected with Ad-HA-14-3-3s or Ad-b-gal, or left uninfected (control). As expected, we found that GFP-MDM2 was located in the nucleus of control cells and cells infected with virus Ad-b-gal (Figure 4a , green) after live-cell images were captured using immunofluorescent microscope. Remarkably, GFP-MDM2's subcellular location was detected in the cytoplasm when cells were infected with adenovirus Ad-14-3-3s (Figure 4a ). We obtained similar results by using 293T cells for studies (Figure 4b) , thus excluding the possibility that this phenomenon is cell type-specific.
To demonstrate the dynamic shuttling process of GFP-MDM2 affected by 14-3-3s, we performed timelapse microscopy and collected live-cell images of cells expressing GFP-MDM2. H1299 cells transfected with GFP-MDM2 and then infected with Ad-14-3-3s were assayed. The time-lapse images showed that green signal from GFP-MDM2 in a representative live cell (indicated by arrowheads) was migrating from the nucleus (white arrowheads) to the cytoplasm (green arrowheads) after Ad-14-3-3s infection (Figure 5a ), helping pinpoint the process and timing (between 29 and 30 h from the starting point) of the sequestering effect of 14-3-3s on MDM2.
MDM2 is known to have p53 nuclear-exporting activity (Geyer et al., 2000) . In light of the observation that 14-3-3s can affect the subcellular location of MDM2, we then determined whether the MDM2-mediated p53 nuclear export is affected when 14-3-3s is expressed. We found that MDM2-mediated cytoplasmic localization of GFP-p53 is reversed by the presence of 14-3-3s (Figure 5b) . Together, 14-3-3s affected the location of MDM2 from the nucleus to the cytoplasm, thereby antagonizing the p53 nuclear exporting activity of MDM2.
14-3-3s blocks various activities of MDM2
To provide the biological significance of antagonizing effects of 14-3-3s toward MDM2, we tested whether 14-3-3s could affect the function of MDM2 in tumorigenesis. It is known that Akt can enhance the activity of MDM2 (Zhou et al., 2001) . We employed cells (Rat1-Akt cells) or animal tumors (induced by Rat1-Akt cells) activated by Akt as models to determine the impact of 14-3-3s on MDM2. Rat1-Akt cells, which have constitutive Akt, were infected with Ad-HA-14-3-3s or Ad-b-gal and subjected to immunoblotting. Interestingly, Ad-14-3-3s-infected Rat1-Akt cells had increased expression of p53 and showed more PUMA expression, Figure 3 The expression of 14-3-3s reduces the stability of MDM2. (a) 14-3-3s decreased the stabilization of MDM2. Cell extracts from H1299 cells transfected with an equal amount of MDM2 and increasing amounts of the Flag-tagged 14-3-3 were immunoblotted with anti-MDM2, anti-Flag and anti-tubulin. (b) 14-3-3s facilitates self-ubiquitination of MDM2. Cell extracts from 293T cells co-transfected with MDM2 (1 mg), His-ubiquitin (1 mg) and increasing amounts of Flag-14-3-3s (0, 1 and 5 mg) were harvested and pulled down using His-bind beads. The protein complexes were probed with anti-MDM2 antibody. (c) MDM2 is stabilized in the cells deficient in 14-3-3s. Lysates of HCT116 14-3-3s À/À and 14-3-3s þ / þ cells were immunoblotted with anti-14-3-3s, anti-MDM2 antibodies and anti-tubulin. (d) Comparison of MDM2 turnover in HCT116 14-3-3s À/À and 14-3-3s þ / þ cells. Cells were treated with cycloheximide for the indicated times. Cell lysates were immunoblotted with anti-MDM2, anti-p53 and anti-tubulin. (e) Levels of MDM2 at each time point in (d) were measured using a densitometer. The remaining level of MDM2 at time 0 was set at 100%. MDM2 remaining is indicated graphically.
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H-Y Yang et al a p53 target involved in apoptosis (Yu et al., 2001) , than Ad-b-gal-infected cells (Figure 6a ). Also, we used animal tumors induced by Rat1-Akt cells to investigate the MDM2 expression under the activity of 14-3-3s. Rat1-Akt cells were infected with Ad-HA-14-3-3s or Ad-bgal. The cells were then implanted into nude mice and observed for tumor formation. We previously showed that tumor growth was observed in Ad-b-gal-treated mice after 15 days; however, tumor volume was dramatically decreased in Ad-HA-14-3-3s-treated mice (studied in Yang et al., 2006) . We obtained tumor samples from these studies and found that levels of MDM2 in tumors obtained from Ad-HA-14-3-3s-treated mice were markedly less than those in Ad-bgal-treated mice (Figure 6b ). Consistently, transduced HA-14-3-3s proteins and higher level of p53 were present in small tumors of Ad-HA-14-3-3s-treated mice, whereas lower level of p53 was observed in larger tumors of Ad-b-gal-treated mice (Figure 6b ). Thus, these results highlight the important roles of 14-3-3s in downregulating MDM2, thereby stabilizing p53 and inhibiting tumor growth. Recently, MDM2 is involved in promoting the degradation of tumor suppressor RB protein (Sdek et al., 2005; Miwa et al., 2006) , and thus contributes to cancer development. In addition, MDM2 is shown to NEDDylate p53, thereby antagonizing the transcriptional activity of tumor suppressor p53 (Xirodimas et al., 2004) . We then examined the impact of 14-3-3s on these biological activities of MDM2 using HCT116 14-3-3sÀ/À and 14-3-3s þ / þ cells. We found that levels of RB protein are diminished in HCT116 14-3-3sÀ/À cells, Figure 5 14-3-3s antagonizes MDM2-meditated p53 nuclear export. (a) Dynamic shuttling process of GFP-MDM2 into the cytoplasm is affected by 14-3-3s. The H1299 cells were transfected with GFP-MDM2 for 24 h and then infected with Ad-HA-14-3-3s for 10 h. Live-cell images were collected at 1-h intervals. The hours indicate the elapsed time since the first picture (24, 29 and 30 h after the infection with Ad-14-3-3s) was taken. Note that GFP-MDM2 (arrowheads) in a representative cell is shuttling from the nucleus (white arrowheads) into the cytoplasm (green arrowheads) after 30 h of infection. (b) Effects of 14-3-3s on MDM2-mediated p53 nuclear exporting. The R1b/L17 cells were transfected with or co-transfected with indicated plasmids encoding GFP-p53, MDM2 or14-3-3s. Live-cell images were captured. Subcellular localization of GFP-p53 (green) is shown. Hoechst 33342 (0.5 mg/ml) was added for DNA staining (blue).
which has a high level of MDM2, compared to HCT116 14-3-3s þ / þ cells (Figure 6c ), suggesting that accumulated MDM2 is active in degrading RB when 14-3-3s is deficient. In addition, we found that HCT116 14-3-3sÀ/À cells exhibited high levels of NEDD8-conjugated p53 as compared with HCT116 14-3-3s þ / þ cells (Figure 6c ), indicating that MDM2 is efficient in NEDDylating p53 when 14-3-3s is disabled.
We then confirmed the variation of MDM2-mediated p53 NEDDylation by performing a NEDDylation assay. H1299 cells were co-transfected with MDM2, p53, pCMV-His-NEDD8 and increasing amount of 14-3-3s. Cells were harvested and analysed by His-Bind resin binding for the presence of His-NEDDylated p53. We found that 14-3-3s antagonized MDM2-mediated p53 NEDDylation (Figure 6d) . Together, these data indicated that 14-3-3s is a pivotal regulator of MDM2 and is involved in blocking a variety of activities of MDM2.
Discussion
MDM2 plays a pivotal role in cancer formation, and its oncogenic activity arises mostly from the elevated activity in degrading p53 (Momand et al., 1998) . Obviously, MDM2 is an important molecular target for rational cancer therapy (Zhang and Wang, 2000) . Recently, the high frequency of downregulation of 14-3-3s in several types of cancer demonstrates that the dysregulation of 14-3-3s plays an important role in human tumorigenesis (reviewed in Lee and Lozano, 2006) . Our study shows that 14-3-3s binds and negatively regulates MDM2. This important biological function antagonizes MDM2-mediated p53 nuclear export, which in turn stabilizes p53. Moreover, studies of 14-3-3s null cells show that disabling of 14-3-3s results in accumulation of MDM2, thereby facilitating MDM2-mediated p53 NEDDylation and RB degradation. Consistently, overexpression of 14-3-3s can block MDM2-mediated activities, and inhibits tumorigenicity by downregulating MDM2 in cancer models. As a cellular inhibitor of MDM2, 14-3-3s should prove useful in the treatment of tumors with elevated MDM2 activity.
It is known that the N-terminal domain of 14-3-3 proteins mediates homodimerization or heterodimerization, while the C-terminal domain is involved in target protein binding (Fu et al., 2000) . As expected, our domain-binding assays indicate that 14-3-3s employs the C-terminal domain to interact with the C-terminal domains of MDM2 or p53 (Figure 2) . Hence, on the basis of these results, we have proposed a working model (Figure 7 ) that incorporates and extends previous findings that 14-3-3s is a positive regulator of p53 (Yang et al., 2003) . As presented in the model, when 14-3-3s is not induced in unstressed cells (Figure 7a ), 14-3-3s may use its C-terminal domain to interact with C-terminal domains of MDM2 or p53, while MDM2 and p53 are still interacting with each other through respective Nterminal domain. The resultant complex does not affect MDM2-mediated p53 degradation in these cells. In DNA-damaged or stressed cells (Figure 7b ), p53 is capable of initiating the transcription of 14-3-3s, leading to a high level of 14-3-3s that may be above a threshold to exert its effect. Increased amounts of 14-3-3s can accelerate MDM2 self-ubiquitination and thus increase proteasome-mediated degradation of MDM2. Hence, 14-3-3s negatively impacts on MDM2 nuclear localization, MDM2-mediated p53 nuclear export, NEDDylation and MDM2-mediated RB degradation. In the meanwhile, high levels of 14-3-3s can stabilize p53, instigate p53 nuclear localization, facilitate tetramerization of p53 (Yang et al., 2003) and potentiate transcriptional activity of p53 (Yang et al., 2003) , inducing p21 (Yang et al., 2003) or PUMA ( Figure 6 ). This model conveniently explains how 14-3-3s interacts with p53 and MDM2 and affects their activities. Cell lysates were immunoblotted with anti-p53, anti-PUMA or anti-HA (for delivered 14-3-3s expression). (b) 14-3-3s inhibited MDM2 expression during tumorigenicity. Rat1-Akt cells were infected with Ad-HA-14-3-3s or Ad-b-gal. 1 Â 10 6 cells were harvested and subcutaneously injected into the flank region of nude mice. Tumors were observed after 2 weeks. Tumor tissues from the sites of implantation from experiment were assessed for expressed proteins by immunoblotting with anti-MDM2, anti-p53 and anti-HA (for delivered 14-3-3s expression). (c) Cell lysates from HCT116 cells were immunoprecipitated with anti-p53 and immunoblotted with anti-NEDD8. Amounts of 14-3-3s, RB and MDM2 are also indicated. (d) 14-3-3s inhibits MDM2-mediated p53 NEDDylation. Cell extracts from 293T co-transfected with MDM2 (1 mg), p53, His-NEDD8 (1 mg) and increasing amounts of Flag-14-3-3s (0, 1 and 5 mg) were harvested and pulled down using His-bind beads. The protein complexes were probed with anti-p53 antibody.
We have used live-cell imaging to indicate that 14-3-3s is able to sequester MDM2 from the nucleus to the cytoplasm ( Figure 5) . The results give a snapshot of sequestering process of MDM2 by 14-3-3s. This phenomenon could be, at least in part, explained by 14-3-3s's capability in inhibiting PKB/Akt activity. Akt can mediate phosphorylation of MDM2 at Ser166, promoting MDM2 nuclear localization (Zhou et al., 2001) . We recently showed that 14-3-3s inhibits Aktmediated kinase activity (Yang et al., 2006) . Presumably, 14-3-3s can impair Akt-mediated MDM2 phosphorylation, which in turn prevents MDM2 nuclear localization.
Recent studies show that MDM2 has p53-independent function in degrading RB (Sdek et al., 2005) . It is shown that disabling MDM2 leads to inhibition of DNA synthesis in an RB-dependent pathway (Sdek et al., 2005) . That MDM2 can degrade RB in a proteasome-dependent pathway provides a possible explanation for such a phenomenon (Sdek et al., 2005; Miwa et al., 2006) . We show that 14-3-3s is required to block MDM2-meditated RB degradation (Figure 6 ), which is consistent with its role as a negative regulator of MDM2 and cell cycle in general.
In addition to ubiquitination activity, MDM2 uses its C-terminal RING domain to promote p53 NEDDylation at three lysine residues of p53 (Xirodimas et al., 2004) . These lysine residues are also the potential ubiquitination sites. Importantly, NEDDylation appears to have a negative impact on the transactivation activity of p53 (Xirodimas et al., 2004) . We show that 14-3-3s can antagonize MDM2-mediated p53 NEDDylation, which in turn will take away the inhibitory effect of NEDDylation on p53 transcriptional activity. These studies are consistent with and extend the finding that 14-3-3s can potentiate p53 transcriptional activity (Yang et al., 2003) .
Together, our data provide compelling evidence that 14-3-3s can function as a negative regulator of MDM2. Targeting MDM2 by the administration of 14-3-3s could be an excellent therapeutic regimen for the treatment of cancers in which the MDM2 is overexpressed or amplified.
Materials and methods
Cell lines and cell culture 293T, R1B/L17 (the mink lung epithelial cell line derivative) (Lee et al., 1995) , H1299 cells (from ATCC, Manassas, VA, USA) and Rat1-akt cells (Zhou et al., 2001) were maintained in Dulbecco's modified Eagle's medium. An HCT116 14-3-3s þ / þ human colon carcinoma cell line and a derivative HCT116 14-3-3sÀ/À cell line were kindly provided by Dr Bert Vogelstein (John Hopkins Oncology Center, Baltimore, MD, USA). and MDM2 (1-440, dl220-437, 50-491) have been previously described (Yang et al., 2003; Wang et al., 2005) . Nuclear export mutant MDM2 (C464A) was provided by Dr Maki (Geyer et al., 2000) . p53 DC16 and DC30 were kind gifts of Yang-Ping Zhang. GFPp53 was kindly provided by Dr G Wahl (Stommel et al., 1999) . GFP-MDM2 was a kind gift from Dr Sudha Shenoy. His-NEDD8 was obtained from Dr Tetsu Karmitani. Cycloheximide and MG132 were from Sigma (St Louis, MO, USA). Antibodies against MDM2 (SMP14, Santa Cruz, Santa Cruz, CA, USA), p53 (DO1, Oncogene Science, Cambridge, MA, Figure 7 A model for the effects of 14-3-3s in regulating MDM2 and p53 in cells.
Plasmids, reagents and antibodies
14-3-3r as a negative regulator of MDM2 H-Y Yang et al USA), p53 (FL393, Santa Cruz Biotechnology, Santa Cruz, CA, USA), 14-3-3s (RDI, Concord, MA, USA), tubulin (B-5-1-2, Sigma), PUMA (Prosci, Poway, CA, USA, bb3), NEDD8 (Sigma), RB (BD Bioscience, Pharmingen, San Jose, CA, USA), HA epitope (12CA5, Babco, Richmond, CA, USA) and Flag epitope (Sigma) were used for immunoblotting or immunoprecipitation. Ad-14-3-3s and Ad-b-gal viruses (Hermeking et al., 1997) were produced as previously described (He et al., 1998) .
In vitro binding assay The analysis was described previously (Yang et al., 2003) .
Ubiquitination and NEDDylation assay
Ubiquitination assay was established as described previously (Yang et al., 2003) . NEDDylation assay is similar to ubiquitination assay, except that His-NEDD8 was used.
Live-cell imaging Live-cell images of H1299, 293T or R1B/L17 cells expressing GFP-MDM2 or GFP-p53 were captured with a cooled Orca-ER CCD camera (Hamamatsu, Japan) mounted on a Zeiss Axiovert 200M microscope. It is fully motorized, equipped with the heated stages, and heat and CO 2 controlled incubators. Hoechst 33342 (0.5 mg/ml) was added for DNA staining.
